𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase

✍ Scribed by Robert P. Hasserjian

Book ID
107648098
Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
1023 KB
Volume
4
Category
Article
ISSN
1865-5785

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Significance of myelofibrosis in early c
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 98 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

Long-term response in accelerated-phase
Long-term response in accelerated-phase chronic myelogenous leukemia with protracted splenic irradiation and ?-interferon
✍ Girinsky, T.; Bonomi, M.; Bayle, C. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 40 KB πŸ‘ 2 views

Forming Assay From CD34 + Bone Marrow Cells Serum a BFU-E/10 2 CD34 + cells Control 1 50.2 Β± 4.6 Control 2 48.5 Β± 14.1 Before chemotherapy 24.4 Β± 6.2 b After chemotherapy 50.5 Β± 6.5 Values are means Β± SD of triplicate cultures. a Control 1; normal AB serum, Control 2; serum from a patient with AILD-

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw